How are you approaching patients with Stage IV EGFR NSCLC who progress on first line TKI and are found to have retained EGFR mutation as well as MET amplification?

Topics: Thoracic Malignancies • Medical Oncology

Answer from: Medical Oncologist at Academic Institution

The nuance here is how the MET amplification was detected and defined. Was it through an NGS platform (such as Guardant) or through FISH-based testing? If the latter, what was the MET gene copy number, and what was the ratio of MET/CEP7?Nonetheless, assuming MET amplification is an accurate bypass s...

Comments

Medical Oncologist at Onc San Antonio
Thank you Dr. @Tejas Patil for your insight, ...

Medical Oncologist at University of Colorado
I would get FISH based testing unless your NGS ass...

Medical Oncologist at New York Methodist Hosp
I have seen responses with increasing osimertinib ...

Medical Oncologist at Onc San Antonio
Thank you for your valuable input.

Medical Oncologist at ProMedica Flower Hospital
@Tejas Patil, I have a patient with oligoprogressi...

Medical Oncologist at University of Colorado
Is the liver lesion within the radiation field whe...

Medical Oncologist at ProMedica Flower Hospital
The new progressive lesion has been treated with S...

Answer from: Medical Oncologist at Academic Institution

I think it is challenging to give a single answer here as there is a lot of heterogeneity here. When MET amplification is driving EGFR TKI resistance, that can be overcome by the addition of a MET inhibitor. The INSIGHT 2 study (Tan et al., Journal of Clinical Oncology 2023) included patients with ...

Related Questions